

JUN 13 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of ~~Hideo KITAMURA~~

Application No. 09 380 372

Filed September 1, 1999

For NOVEL CELL LINES AND SCREENING METHODS

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington D C 20231

Art Unit 1651

Examiner L LANKEFORD JR

Washington, D C

Atty's Docket KITAMURA

Date June 13, 2001

RECEIVED

JUN 13 2001

TECH CENTER 1600 2001

Sir

Transmitted herewith is a [X] Amendment []

in the above-identified application

[] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted
 [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed
 [] No additional fee is required
 [XX] The fee has been calculated as shown below

	(Col 1)	(Col 2)	(Col 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID
TOTAL	* 16	MINUS	** 20
INDEP	* 2	MINUS	*** 3
FIRST PRESENTATION OF MULTIPLE DEP CLAIM			

SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
x 9	\$		x 18	\$
x 40	\$		x 80	\$
+ 135	\$		+ 270	\$
ADDITIONAL FEE TOTAL			TOTAL	

- * If the entry in Col 1 is less than the entry in Col 2, write "0" in Col 3
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col 1 of a prior amendment of the number of claims originally filed

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[] First - \$ 55 00
 [] Second - \$ 195 00
 [] Third - \$ 445 00
 [] Fourth - \$ 695 00

Month After Time Period Set

[] Less fees (\$ _____) already paid for _____ month(s) extension of time on _____

Other Than Small Entity

Response Filed Within

[] First - \$ 110 00
 [] Second - \$ 390 00
 [XX] Third - \$ 890 00
 [] Fourth - \$ 1390 00

Month After Time Period Set

[] Please charge my Deposit Account No. 02-4035 in the amount of \$ _____


[XX] Credit Card Payment Form, PTO-2038 is attached, authorizing payment in the amount of \$ 890.00.

[] A check in the amount of \$ _____ is attached (check no.)

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By 
 ALLEN C. YUN
 Registration No. 37,971



RECEIVED

JUN 13 2001

TECH CIV E&E 1600 2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Art Unit: 1651
Hidetomo KITAMURA Examiner: M. L. Mather, Jr.
Appln. No.: 09/380, 370 Washington, D.C.
Filed: September 1, 1999) June 13, 2001
For: NOVEL CELL LINES AND) Atty. Docket: KITAMURA-1
SCREENING METHODS...)
)
)

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of December 20, 2000, petition and payment for a three month extension of time being attached hereto, please amend as follows:

IN THE CLAIMS

Please replace claims 1, 4, 5, 8, 15, and 18 with new rewritten claims 1, 4, 5, 8, 15, and 18 as follows below. A marked up version of the amended claims to show the changes made is attached hereto.

1 (Twice-amended). A cell line capable of differentiating into chondrocytes and capable of differentiating into adipocytes, which cell is derived from a normal adult animal.
